Zweig DiMenna Associates LLC Purchases Shares of 99,500 Roivant Sciences Ltd. (NASDAQ:ROIV)

Zweig DiMenna Associates LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 99,500 shares of the company’s stock, valued at approximately $1,177,000.

Several other institutional investors also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares during the period. Covestor Ltd grew its holdings in shares of Roivant Sciences by 9.1% during the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after purchasing an additional 1,605 shares in the last quarter. US Bancorp DE increased its position in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the period. Quarry LP raised its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Gladius Capital Management LP bought a new position in Roivant Sciences in the third quarter worth $35,000. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Down 0.5 %

Shares of Roivant Sciences stock opened at $11.15 on Friday. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The stock has a market capitalization of $8.12 billion, a P/E ratio of 1.98 and a beta of 1.27. The company has a 50-day simple moving average of $11.75 and a 200 day simple moving average of $11.60.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the sale, the chief operating officer now owns 606,525 shares in the company, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction dated Monday, January 13th. The shares were bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 1,942,629 shares of company stock valued at $23,034,486. Corporate insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.